



nanik siti aminah <nanik-s-a@fst.unair.ac.id>

Confirming submission to Heliyon

1 message

Heliyon <em@editorialmanager.com>
Reply-To: Heliyon <info@heliyon.com>
To: Nanik Siti Aminah <nanik-s-a@fst.unair.ac.id>

Fri, Jul 17, 2020 at 7:51 PM

CC: "Erlinda Rhoamatul Laili" erlinda.rhoamatul.laili-2015@fst.unair.ac.id, "Mohamad Rafi" mra@ipb.ac.id, "Abdul Rochman" abdulkimfar@gmail.com, "Muhamad Insanu" insanu@fa.itb.ac.id, "Khun Nay Win Tun" khun.nay.win-2017@fst.unair.ac.id

This is an automated message.

Secondary Metabolite Compounds from Sida Genus and Their Bioactivity-A review

Dear Dr Aminah,

We have received the above referenced manuscript you submitted to Heliyon. It has been assigned the manuscript number HELIYON-D-20-05079. To track the status of your manuscript, please log in as an author at <https://www.editorialmanager.com/heliyon/>, and navigate to the "Submissions Being Processed" folder.

Thank you for submitting your work to Heliyon, an open access journal that is part of the Cell Press family.

Kind regards,
Heliyon

More information and support

You will find information relevant for you as an author on Elsevier's Author Hub: <https://www.elsevier.com/authors>

FAQ: How can I reset a forgotten password?

https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/

For further assistance, please visit our customer service site: <https://service.elsevier.com/app/home/supporthub/publishing/>

Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/heliyon/login.asp?a=r>). Please contact the publication office if you have any questions.

Decision on submission HELIYON-D-20-05079 to Heliyon

3 messages

Heliyon <em@editorialmanager.com>
Reply-To: Heliyon <info@heliyon.com>
To: Nanik Siti Aminah <nanik-s-a@fst.unair.ac.id>

Thu, Oct 8, 2020 at 4:41 PM

Manuscript. Number.: HELIYON-D-20-05079
Title: Secondary Metabolite Compounds from Sida Genus and Their Bioactivity-A review
Journal: Heliyon

Dear Dr. Aminah,

Thank you for submitting your manuscript to Heliyon.

We have completed the review of your manuscript and a summary is appended below. The reviewers recommend major revisions are required before publication can be considered.

If you are able to address all reviewer comments in full, I invite you to resubmit your manuscript. We ask that you respond to each reviewer comment by either outlining how the criticism was addressed in the revised manuscript or by providing a rebuttal to the criticism. This should be carried out in a point-by-point fashion as illustrated here: <https://www.cell.com/heliyon/guide-for-authors#Revisions>

To allow the editors and reviewers to easily assess your revised manuscript, we also ask that you upload a version of your manuscript highlighting any revisions made. You may wish to use Microsoft Word's Track Changes tool or, for LaTeX files, the latexdiff Perl script (<https://ctan.org/pkg/latexdiff>).

To submit your revised manuscript, please log in as an author at <https://www.editorialmanager.com/heliyon/>, and navigate to the "Submissions Needing Revision" folder. Your revision due date is Nov 17, 2020.

We understand that the global COVID-19 situation may well be causing disruption for you and your colleagues. If that is the case for you and it has an impact on your ability to make revisions to address the concerns that came up in the review process, please let us know so we can discuss with you potential revision deadline extensions. Please also note that Heliyon focuses on technically correct science and so you are only expected to include revisions that are necessary to ensure that the content and the conclusions of the research are technically correct.

I look forward to receiving your revised manuscript.

Kind regards,
Salvatore Genovese
Associate Editor - Chemistry
Heliyon

Editor and Reviewer comments:

Reviewer #1: Methods:In the abstract the authors didnot talked about the meaning of secundary metabolite of sida and also the family name of sida, why did the authors choose to research on the secondary metabolites of sida?. The authors spoke about some pharmacological activities but did not made it clear whether the crude of sida or pure compounds (secondary metabolites) that exhibited those activities. The authors have to do a lot of proofreading and correct all the spelling mistakes.

Results:I would expect the authors to differentiate clearly between the specie name and scientific name in their botanical description for all the speices of the genus Sida. There should be a sub heading Pharmacological activites or propertied for the authors to tell the reader what are the types of extracts, how the secondary metabolite compounds are extracted and how the bioactivities are done. Authors also need to proofread for correction.

Interpretation:The conclusions are good and relevant, assuming the above modifications are made in order to properly justify them. In summary, it's the basis for a really interesting and relevant review article, on a timely and important subject, but unfortunately I'm afraid it needs a bit of work before publication if it is to be properly useful to the reader.

Other comments:The authors have no recommendations and this is important in every review paper.

The conclusions are good and relevant, assuming the above modifications are made in order to properly justify them. In summary, it's the basis for a really interesting and relevant review article, on a timely and important subject, but unfortunately I'm afraid it needs a bit of work before publication if it is to be properly useful to the reader.

Reviewer #2: Methods:

The methods used to search for evaluation resources are not mentioned, it is important to mention the search engines/databases used, in addition to the criteria used to determine the inclusion of the article in this review.

For example:

- A literature search on PubMed was conducted to gather articles in this study using the MeSH terms.....
- The following criteria were used to determine article inclusion in this review: (1) original research articles written in English; (2) randomized trial;

Results:

1-You did not devote a specific section to the results: It is very important to highlight the results that you obtained through your research on this topic in the previous literature, and your presentation of these results must be clear and appropriate.

2- is necessary for such type of research that you represent the results you obtained from previous studies or your conclusions with tables and figures that make it easy for the reader to reach the largest amount of information easily and quickly.

Interpretation:

1-The discussion of the findings was not critical, but rather a descriptive summary of the topic. There is a lot of contradictory research in this area, you should include an element of debate and present both sides of the argument. You must use this review paper to resolve the conflict between contradictory studies.

2-You did not adopt any hypothesis, the review article should be based on the adoption of a theory by the author and it should take into account different approaches, then the author's hypothesis against the prevailing opinion against the undisputed facts is precisely determined.

Other comments:

Dear authors, I thank you for all your efforts

Dear Sirs, it is no secret to you that the literature review is a comprehensive and broad set of facts related to the subject of study, and it serves as the backbone of successful biomedical research. Ideal selection of related topics is the first step towards an educational review. The benefit of this type of writing is that it contains detailed information on progress made in past years with an emphasis on future prospects. The progress of science depends on the development of an agreed version of the current scientific facts. This compliance is created and modified by various activities, including the creation, peer review, and publishing of review papers. A good review paper can clarify the state of knowledge, explain obvious contradictions, define the research needed, and even create a consensus where there was no consensus before.

From here it becomes clear that the review is not a collection of some information and merely listing it. Rather, the scientific review must be based on main pillars, unfortunately, the review that you submitted did not meet these conditions and we will summarize that with the following axes:

1- Abstract

-The main purpose of this review is not sufficiently clarified.

-The lack of clarity of the findings of this reference study, in addition to neglecting to mention the methods used to collect the results, viewpoints of previous research, and the conclusions obtained.

2-Introduction

-Your presentation of the topic should be beginning with a general view, give some contexts, and the necessary reasons must be explained that led you to review this topic. Define the research question clearly and provide sufficient justification for it.

-There is no indications that your article will contribute something new to the field.

-It is very important to define the scope of your review so that it is manageable, not too lengthy, or too small; It is necessary to focus on recent developments if the field is well established.

3-Methodology:

The methods used to search for evaluation resources are not mentioned, it is important to mention the search engines/databases used, in addition to the criteria used to determine the inclusion of the article in this review.

For example:

- A literature search on PubMed was conducted to gather articles in this study using the MeSH terms.....
- The following criteria were used to determine article inclusion in this review: (1) original research articles written in English; (2) randomized trial;

4-Results:

-You did not devote a specific section to the results: It is very important to highlight the results that you obtained through your research on this topic in the previous literature, and your presentation of these results must be clear and appropriate.

- is necessary for such type of research that you represent the results you obtained from previous studies or your conclusions with tables and figures that make it easy for the reader to reach the largest amount of information easily and quickly.

5-Discussion and Conclusions

The discussion of the findings was not critical, but rather a descriptive summary of the topic. There is a lot of contradictory research in this area, you should include an element of debate and present both sides of the argument. You must use this review paper to resolve the conflict between contradictory studies.

You did not adopt any hypothesis, the review article should be based on the adoption of a theory by the author and it should take into account different approaches, then the author's hypothesis against the prevailing opinion against the undisputed facts is precisely determined.

The main message for this review is unclear?

1- It is not easy even for an expert to know what the authors are trying to say or what they are trying to reach.

2- In fact, the authors do not say anything at all. Rather, this review is an account of the results of previous research only without discussion or analysis.

Others

There are many errors, which include not mentioning the references in the list of references, especially since these references are mentioned in the text, and we remind you to pay attention to formulating the phrases in a proper language and bypassing some spelling mistakes.

I will give you some examples

Sutradhar et al., (2007)

Chaves et al., (2013),

mentioned in the text and not mentioned in the list of references

Krapovickas., 2006

Branda J. L et al., 2017

(Xuyen Do Thi., 2006)

Ghosh and Dutta, (1930)

Dalimarta S., 2003: The author's name is incorrect

Ethnomedisinal: Wrongly written

Reviewer #3: Methods:

Results:

Interpretation:

Other comments:

More information and support

FAQ: How do I revise my submission in Editorial Manager?

https://service.elsevier.com/app/answers/detail/a_id/28463/supporthub/publishing/

You will find information relevant for you as an author on Elsevier's Author Hub: <https://www.elsevier.com/authors>

FAQ: How can I reset a forgotten password?

Decision on submission HELIYON-D-20-05079R2 to Heliyon

1 message

Heliyon <em@editorialmanager.com>
Reply-To: Heliyon <info@heliyon.com>
To: Nanik Siti Aminah <nanik-s-a@fst.unair.ac.id>

Thu, Mar 4, 2021 at 12:46 PM

Ms. No.: HELIYON-D-20-05079R2
Title: Secondary Metabolite Compounds from Sida Genus and Their Bioactivity
Journal: Heliyon

Dear Dr. Aminah,

Thank you for submitting your manuscript to Heliyon.

We have now received all of the editor and reviewer comments on your recent submission to Heliyon. Your paper will become acceptable for publication after implementation of minor formatting and/or administrative changes outlined below.

To submit your revised manuscript, please log in as an author at <https://www.editorialmanager.com/heliyon/>, and navigate to the "Submissions Needing Revision" folder under the Author Main Menu. When submitting your revised manuscript, please ensure that you upload your most recent document with the "Revised manuscript file - highlighting revisions made" item type.

Kind regards,

Like Wang
Editorial Assistant
Heliyon

Embargo

Embargos are not automatically set for papers published in Heliyon. Papers appear online a few days after acceptance. To request a media embargo and/or publication on a specific date, please reach out to the Heliyon team (info@heliyon.com) as soon as possible and we will do our best to accommodate your request.

Editor and Reviewer comments:

Editorial Office:

Please make sure all figures are numbered in sequence.

Please make sure that all of the figures are referenced in the text of manuscript.

All images included in your manuscript must be either original images or, if published images are being reused, written approval from the copyright holder must be provided. More information on the reuse of images and how to request permission can be found here: <https://www.elsevier.com/about/policies/copyright/permissions>. As part of figures 1, 2, 3, 4, 5, 6, 7, 8 have been previously published, please either provide written consent from the copyright holder to reuse the image when resubmitting or replace with a previously unpublished image.

Please confirm the following funding statement is correct. Alternatively, if this is incorrect, please provide a corrected statement.

"Dr. Nanik Siti Aminah was supported by Hibah Riset Kolaborasi Indonesia 2020 (10/RKI/Thp-I/2020)."

Data in Brief (optional):

We invite you to convert your supplementary data (or a part of it) into an additional journal publication in Data in Brief, a multi-disciplinary open access journal. Data in Brief articles are a fantastic way to describe supplementary data and associated metadata, or full raw datasets deposited in an external repository, which are otherwise unnoticed. A Data in Brief article (which will be reviewed, formatted, indexed, and given a DOI) will make your data easier to find,

Publishing Agreement completed for your article [HLY_e06682]

1 message

Elsevier - Author Forms <Article_Status@elsevier.com>
To: nanik-s-a@fst.unair.ac.id

Wed, Mar 31, 2021 at 9:42 PM

ELSEVIER

Dear Dr. Aminah,

Thank you for completing the Publishing Agreement Form for your article *Secondary Metabolite Compounds from Sida Genus and Their Bioactivity*. Please find attached a copy of the "Journal Publishing (License) Agreement" which you completed online on March 31, 2021.

If you have any questions, please do not hesitate to contact us. To help us assist you, please quote our article reference HLY_e06682 in all correspondence.

Now that your article has been accepted, you will want to maximize the impact of your work. Elsevier facilitates and encourages authors to share their article responsibly. To learn about the many ways in which you can share your article whilst respecting copyright, visit: www.elsevier.com/sharing-articles.

We are committed to publishing your article as quickly as possible.

Kind regards,
Elsevier Researcher Support

Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2018 Elsevier Ltd | [Privacy Policy](http://www.elsevier.com/privacypolicy) <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add article_status@elsevier.com to your address book or safe senders list.



Track your article [HLY_e06682] accepted in Heliyon

1 message

Elsevier - Article Status <Article_Status@elsevier.com>
To: nanik-s-a@fst.unair.ac.id

Wed, Mar 31, 2021 at 1:06 PM

ELSEVIER

Track your article!

Dear Dr. Aminah,

Your article *Secondary Metabolite Compounds from Sida Genus and Their Bioactivity* will be published in Heliyon.

To track the status of your article throughout the publication process, please use our article tracking service:

<https://authors.elsevier.com/tracking/article/details.do?aid=6682&jid=HLY&surname=Aminah>

For help with article tracking go to [Elsevier Support](#).

We are committed to publishing your article as quickly as possible. We will therefore send you an alert of each next step in the production process where your involvement is required.

Once the expected dispatch date of your proofs is available, you will be automatically alerted by e-mail.

Yours sincerely,

Elsevier Researcher Support

Have questions or need assistance?

Please do not reply to this automated message.

For further assistance, please visit our [Elsevier Support Center](#) where you search for solutions on a range of topics and find answers to frequently asked questions.

You can also talk to our researcher support team by phone 24 hours a day from Monday-Friday and 24/7 by live chat and email.

© 2018 Elsevier Ltd | [Privacy Policy](#) <http://www.elsevier.com/privacypolicy>

Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom, Registration No. 1982084. This e-mail has been sent to you from Elsevier Ltd. To ensure delivery to your inbox (not bulk or junk folders), please add article_status@elsevier.com to your address book or safe senders list.

